Piper Sandler analyst Rob Owens maintains GitLab (NASDAQ:GTLB) with a Overweight and lowers the price target from $67 to $60.
Dyne Therapeutics Announces First Patient Dosed In Phase 1/2 DELIVER Clinical Trial Of DYNE-251 For The Treatment Of Duchenne Muscular Dystrophy
Data from Global, Multiple Ascending Dose DELIVER Trial Anticipated in the Second Half of 2023 -
- Dyne to Host “Spotlight on the Clinic” Virtual Event on September 12 -
WALTHAM, Mass., Sept. 06, 2022
